

# Active tuberculosis drug-safety monitoring and management (aDSM)

Framework for implementation

THE  
**END TB**  
STRATEGY



World Health  
Organization



# **Active tuberculosis drug-safety monitoring and management (aDSM)**

**Framework for implementation**



**World Health  
Organization**

© **World Health Organization 2015**

All rights reserved. Publications of the World Health Organization are available on the WHO website ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications -whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website ([www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Editing and design by Inis Communication – [www.iniscommunication.com](http://www.iniscommunication.com)

Printed by the WHO Document Production Services, Geneva, Switzerland WHO/HTM/TB/2015.28

# Contents

|   |    |
|---|----|
| Abbreviations . . . . .   | iv |
| Background . . . . .  | 1  |
| Introducing active TB drug-safety monitoring and management (aDSM) and applicable terminology . . . . . | 3  |
| Objectives of aDSM . . . . .  | 5  |
| Implementing aDSM . . . . .   | 6  |
| Support to the implementation of aDSM . . . . .   | 10 |
| <b>Annex 1.</b> List of contributors. . . . .   | 12 |
| <b>Annex 2.</b> Glossary of terms for aDSM . . . . .  | 13 |
| <b>Annex 3.</b> Adverse events of clinical significance or special interest for aDSM. . . . .           | 15 |
| <b>Annex 4.</b> Clinical and laboratory testing schedule for aDSM . . . . .                             | 16 |
| <b>Annex 5.</b> Alert for serious adverse events to the TB programme. . . . .                           | 17 |
| References . . . . .  | 19 |

# Abbreviations

|               |  |
|---------------|--|
| <b>ADR</b>    | adverse drug reaction  |
| <b>aDSM</b>   | active tuberculosis drug-safety monitoring and management        |
| <b>AE</b>     | adverse event  |
| <b>ALT</b>    | alanine aminotransferase   |
| <b>AST</b>    | aspartate aminotransferase                                       |
| <b>GDF</b>    | Global Drug Facility   |
| <b>GTB</b>    | Global TB Programme  |
| <b>EMP</b>    | WHO Essential Medicines and Health Products Department           |
| <b>KNCV</b>   | KNCV Tuberculosis Foundation, Netherlands                        |
| <b>MDR-TB</b> | multidrug-resistant TB   |
| <b>MSF</b>    | Médecins Sans Frontières   |
| <b>NPV</b>    | national pharmacovigilance system                                |
| <b>NTP</b>    | national TB programme  |
| <b>PMDT</b>   | programmatic management of drug-resistant TB                     |
| <b>SAE</b>    | serious adverse event  |
| <b>SGOT</b>   | serum glutamic-oxaloacetic transaminase                          |
| <b>SGPT</b>   | serum glutamic pyruvic transaminase                              |
| <b>TB</b>     | tuberculosis   |
| <b>TDR</b>    | Special Programme for Research and Training in Tropical Diseases |
| <b>TSH</b>    | thyroid stimulating hormone                                      |
| <b>ULN</b>    | upper limit of normal  |
| <b>USAID</b>  | United States Agency for International Development               |
| <b>XDR-TB</b> | extensively drug-resistant TB                                    |
| <b>γGT</b>    | gamma glutamyl transferase                                       |

# Background

Health programmes that systematically monitor patient safety are at an advantage to prevent and manage adverse drug reactions (ADRs), as well as improve health-related quality of life and treatment outcomes. National tuberculosis programmes (NTPs) that actively pursue drug-safety monitoring and management are also better prepared to introduce new tuberculosis (TB) drugs and novel regimens.

The prospect of new anti-TB drugs and use of novel regimens led WHO to release its first implementation manual for pharmacovigilance of anti-TB drugs in 2012 (1). Later in 2012, WHO provided interim advice that the use of shorter regimens for multidrug-resistant TB (MDR-TB) be accompanied by the collection of drug-safety data within a framework of observational research (2). In 2013 and 2014, the WHO interim policies on bedaquiline and delamanid recommended active pharmacovigilance as one of the five conditions to be met when using these drugs to treat MDR-TB patients (3,4).

NTPs and other stakeholders are now starting to introduce new anti-TB drugs and novel MDR-TB regimens according to WHO recommendations. A number of programmes managing MDR-TB patients have also introduced active pharmacovigilance to monitor drug-safety and take early action to avert treatment interruption and other unfavourable patient outcomes (5–7).

The application of pharmacovigilance methods (such as cohort event monitoring) described in the 2012 implementation manual for pharmacovigilance of anti-TB drugs in 2012 (1), was largely based on experience with the use of drugs for malaria, human immunodeficiency virus (HIV) and noncommunicable diseases. This however led to practical questions related to the implementation of drug-safety monitoring alongside other components of programmatic management of drug-resistant TB (PMDT).

The lack of familiarity of many TB practitioners with the principles of drug-safety monitoring and the limited capacity of national drug-safety authorities in some countries to provide the necessary support, generated a demand for more explicit guidance. A recent survey conducted by Médecins Sans Frontières (MSF) and the Stop TB Partnership Global Drug Facility (GDF) in the 27 high MDR-TB burden countries, showed concerns about ADRs being one of the main barriers to the introduction of bedaquiline and delamanid (MSF/GDF, unpublished information).

Several stakeholders expressed concern that the introduction of new anti-TB drugs may be slowed down or even prevented due to a lack of capacity for countries to mount active pharmacovigilance. In response, the WHO Global TB Programme (WHO/GTB) convened key technical and funding agencies to a meeting in Geneva, Switzerland on 28–29 July 2015

to discuss essential requirements for the implementation of active pharmacovigilance and proper management of ADRs when introducing new anti-TB medicines or novel MDR-TB regimens. This document reflects the consensus achieved during this meeting and in subsequent discussions involving NTP managers of selected countries and the WHO Essential Medicines and Health Products Department (see list of contributors in [Annex 1](#)).

Other WHO documents – particularly the *Companion handbook to the WHO guidelines for the programmatic management of drug-resistant TB* (henceforth termed “PMDT Handbook” in this document) (8), *Policy implementation package for new TB drug introduction* (9), and the current WHO/GTB website on TB drug safety as well as the associated frequently asked questions (10) – will be updated accordingly.



# Introducing active TB drug-safety monitoring and management (aDSM) and applicable terminology

Many TB practitioners are unfamiliar with the concept of ‘cohort event monitoring’ and other conventional terminology of pharmacovigilance, making it difficult for them to follow recent recommendations for introduction of a drug-safety monitoring component in PMDT programmes (11,12). It is important to remember that not all countries are at equal levels of maturity in implementing general drug safety and pharmacovigilance activities.

This document therefore outlines the agreed ‘essential requirements for active drug-safety monitoring and management in patients on treatment for drug-resistant TB’.<sup>1</sup> It proposes key terms that were adapted to the specific context of active TB drug-safety monitoring (see [Annex 2](#) for a glossary of the main terms). This adaptation should help the TB community to speak the same language while implementing the required drug-safety activities.

The term ‘active TB drug-safety monitoring and management’ (aDSM) defines active and systematic clinical and laboratory assessment of patients while on treatment. aDSM applies to patients on treatment with: (i) new anti-TB drugs; (ii) novel MDR-TB regimens; or (iii) extensively drug-resistant TB (XDR-TB) regimens, in order to detect, manage and report suspected or confirmed drug toxicities (see [Box 1](#)).

The recording and reporting of aDSM primarily target serious adverse events (SAEs) as a core requirement. PMDT sites with additional resources may also monitor other AEs, which are of clinical significance or of special interest to the PMDT programme, as part of an extended aDSM approach (see below and also [Annexes 2 and 3](#)).

The appropriate and timely management of all AEs and ADRs is an integral component of aDSM and patient care. Further details on the management of ADRs are included elsewhere (see chapter 11 of the PMDT Handbook (8)).

Setting up aDSM for patients on treatment for drug-resistant TB implies additional responsibilities and resource needs. In contrast to the surveillance of drug resistance and treatment outcomes, the active systematic monitoring of the occurrence of SAEs is relatively new to TB programmes. Implementation, management and supervision necessary for aDSM should be systematically built into the PMDT component of the TB programme and conducted in step with other activities related to patient care and monitoring.

---

<sup>1</sup> While drug-safety issues are also relevant in the management of drug-susceptible TB, the safety profiles of first-line TB drugs are well described and not covered by this document.

Close coordination of aDSM activities with main pharmacovigilance structures at the country level is essential to avoid overlap and duplication. Even countries with mature conventional pharmacovigilance systems may need to establish an aDSM component within PMDT programmes to ensure that patients are adequately monitored and all SAEs are detected and reported rapidly.

**BOX 1. TB PATIENTS TO WHOM aDSM APPLIES**

- MDR-TB and XDR-TB patients treated with new medicines, such as bedaquiline or delamanid.
- MDR-TB patients enrolled on treatment with novel regimens, such as those much shorter than the ones currently recommended by WHO.
- All other XDR-TB patients on second-line treatment (these regimens often include multiple repurposed drugs).

Once these groups of patients are covered, aDSM can be extended to other patients on treatment with conventional MDR-TB regimens, depending on the resources available and the national policy.

# Objectives of aDSM

aDSM is not expected to meet all criteria for conventional cohort event monitoring. The overall objectives of aDSM are to reduce risks from drug-related harms in patients on second-line treatment for drug-resistant TB and to generate standardized aDSM data to inform future policy updates on the use of such medicines.

aDSM includes **three essential activities** to achieve these objectives:

1. Patients targeted for aDSM should undergo active and systematic clinical and laboratory assessment during treatment to detect drug toxicity and AEs. Proposed schedules have been developed for use in patients on shorter regimens or on new medications (5,8).
2. All AEs detected should be managed in a timely manner in order to deliver the best possible patient care. Management of AEs is beyond the scope of this note and further details are provided in other implementation documents, such as the PMDT Handbook (8).
3. Standardized data should be systematically collected and reported for any detected SAE.<sup>2</sup> These will eventually be used to characterize the types of SAEs, assess the safety of the treatment, and inform future policy on the use of these medicines.

All SAEs detected should be reported to the national authority responsible for pharmacovigilance according to individual country requirements (including time limits for reporting) and regularly assessed for causality.

WHO will work with partners to establish a global database for aDSM to enhance the detection of new signals and inform future updates of global policies on the use of anti-TB drugs and novel regimens. This is distinct from existing mechanisms for the global coordination of spontaneous reports from national pharmacovigilance systems.

There are three levels of monitoring in aDSM:

1. **Core package:** requiring monitoring for and reporting of all SAEs.
2. **Intermediate package:** includes SAEs as well as *AEs of special interest*.<sup>3</sup>
3. **Advanced package:** includes all *AEs of clinical significance*.<sup>3</sup>

All PMDT sites treating eligible patients with new anti-TB drugs, novel MDR-TB regimens or for XDR-TB require the core package. These treatment centres should, as a minimum, also take part in spontaneous reporting of ADRs as required by local regulations. Expansion of aDSM should be implemented in a phased approach while all resources needed are mobilized.

---

<sup>2</sup> Countries and stakeholders may also monitor other AEs of special interest or clinical significance (see next section).

<sup>3</sup> See Annexes 2 and 3 for definitions of these terms.

# Implementing aDSM

Based on the experience of successful implementation of other care and monitoring components of PMDT programmes, eight key steps have been identified for programmes to follow when introducing aDSM (Figure 1).

Figure 1. **Key steps to implementing aDSM**

- (i) Create a national coordinating mechanism for aDSM**
- (ii) Develop a plan for aDSM**
- (iii) Define management and supervision roles and responsibilities**
- (iv) Create standard data collection materials**
- (v) Train staff for collection of data**
- (vi) Define schedules and routes for data collection and reporting**
- (vii) Consolidate aDSM data electronically**
- (viii) Develop (or use existing) capacity for signal detection and causality assessment**

Ideally, all eight steps should be in place before patients are enrolled on treatment with new drugs, novel MDR-TB regimens or XDR-TB regimens. As this may not always be feasible, two steps – *step (iv)* create standard data collection materials (see [Annexes 4 and 5](#) for examples of data collection forms) and *step (v)* train staff for collection of data – are essential ahead of any patient enrolment.

By having these minimum conditions in place there is less likelihood of data getting lost and of opportunities to manage AEs and ADRs being missed.

The responsibility for the coordination of aDSM at the national level should be assigned to an existing TB expert body, such as the MDR-TB committee (or consilium) or the technical

working group on new drugs. These committees should primarily have scientific and clinical expertise for MDR-TB care and drug safety monitoring and also include expertise important for management and communication (e.g. funding, advocacy, patient representation). Until such a group is tasked with this role, the NTP needs to assign someone to coordinate the necessary aDSM activities and ensure that the two key steps mentioned above are in place prior to patient enrolment.

The aDSM plan should clearly define the activities and standard operating procedures, including the plan for data collection, reporting of indicators, analyses and communication. The final document should be incorporated within national TB or PMDT guidelines. Local and/or international experts in drug safety as well as the national pharmacovigilance centre should be engaged.

While some of the data collection tools for aDSM are separate from those used for routine PMDT programme monitoring, the process should be integrated with other cohort-based monitoring for bacteriological response and outcomes that have been a standard feature of the PMDT component of TB programmes for several years (see chapter 2 and annexes of the PMDT Handbook (8)). WHO is working closely with NTPs and other partners towards further integration of aDSM within routine PMDT programme monitoring.

In the core package of aDSM, clinical and laboratory test records at baseline (treatment initiation) and during regular reviews (e.g. monthly intervals) should be integrated into an expanded version of the programmatic MDR-TB (second-line TB) Treatment Card (see [Annex 4](#) for an example). The treatment initiation form should be completed before the start of treatment (to document any abnormality that could later be confused with a drug-related SAE) and the review form should be completed at scheduled encounters with the patient. In addition, information on SAEs occurring in-between visits should also be captured using the same forms.

A standard form (in paper or electronic format) to alert the programme when any SAE occurs will need to be developed (see [Annex 5](#) for an example). The content of the form could be similar to the one used by the national pharmacovigilance centre for spontaneous reporting.

For the intermediate and advanced packages of aDSM, additional data collection forms will have to be used to record data at baseline and during regular follow-up. Templates of such forms have been developed and can be adapted to individual programme needs (13).

Staff at the different levels of health services should be informed and trained on the use of new anti-TB drugs or novel regimens ahead of any patient enrolment. This training should include instruction on the completion of aDSM forms. It is important that this activity is completed ahead of any patient enrolment to ensure timely identification of AEs that need to be managed, and proper and complete collection and reporting of information.

All AEs detected during routine clinical patient care should lead to an appropriate and timely management response in order to limit potential harms to the patient. *In terms of monitoring, the minimum requirement for aDSM is that all SAEs be registered and reported, regardless of their severity or whether they have been attributed to any of the medicines to which the patient is exposed.*

Some centres with sufficient resources may be designated as 'sentinel sites' and undertake additional monitoring to the one required by the core package of aDSM, such as the reporting of AEs of special interest or AEs of clinical significance (see above). In many countries, reporting of ADRs to the national pharmacovigilance centre is mandated by law. All public and private health services, including TB practitioners should comply with the national legal requirements for such reporting.

The creation of an electronic database – or preferably the adaptation of an existing TB patient database to accommodate the additional data fields required – is an important step in aDSM implementation. It will ensure the standardization and safekeeping of data. If data are collected on paper forms these need to be entered regularly into the electronic database. The management of data in electronic format is indispensable and will facilitate the sharing of data, as well as generation of indicators and analysis.


Measures should be taken to avoid duplication of work by revising existing databases, ensuring interoperability of data management systems, consulting with local pharmacovigilance authorities and granting access rights to users for different data as needed (see [Figure 2](#)). The roles and responsibilities for data management and analysis should be specified in the aDSM plan to avoid the creation of parallel systems of ADR reporting and make use of the best possible expertise and capacity in the country on drug safety.

The ultimate purpose of systematic data collection within aDSM is to enable causality assessment for SAEs, determine their frequency (rates) and detect signals. Physicians skilled in MDR-TB management already attempt to assess relationships between drugs and ADRs and take appropriate clinical action. Nevertheless, formal causality assessment is a separate process that requires involvement of other experts. In a number of countries, the capacity of the national pharmacovigilance centres to conduct formal causality assessment is very limited but where such capacity exists it should be availed of.

The NTP staff should acquire the skills necessary to undertake essential activities related to aDSM. This is a long-term goal but needs to be started as part of the plan to introduce new anti-TB drugs and novel MDR-TB regimens. Local and/or international expertise in causality assessment needs to be sought by the programme to carry out such capacity building. WHO is also working with partners to accelerate such capacity-building efforts.

Figure 2. Generic model of aDSM within drug-safety structures at the national level

aDSM should be adapted to the local situation to avoid the creation of parallel systems of reporting



## Support to the implementation of aDSM

The implementation of aDSM by the NTP should be facilitated by familiarity with the concept of cohort-based follow-up of patients, which is the basis for monitoring and evaluation of TB and MDR-TB treatment programmes. To date, a number of countries have successfully integrated clinical and laboratory testing schedules for active drug-safety monitoring within the TB patient cohort framework that they use to monitor treatment response and outcomes (5,6). The testing schedules used in these projects have largely followed those generally recommended when second-line TB drugs are used (8).

Experience from observational studies of shorter regimens for MDR-TB has shown that active drug-safety monitoring can be feasibly implemented within programmes if dedicated funding is provided and staff are properly trained. Most of the additional resources are needed to undertake clinical testing (e.g. electrocardiography, audiometry) and laboratory analyses, and to collect safety data.

It is envisaged that once the right skills are acquired and links are established with appropriate experts in drug safety, causality assessment and signal detection could be organized within the PMDT programme with appropriate capacity building and support from drug-safety experts (if such capacity is missing at the national pharmacovigilance system). More work is needed to quantify the costs of aDSM and these will eventually be reflected in the tools to help users with budgeting.

While clinicians treating patients with second-line anti-TB drugs are usually familiar with clinical monitoring for adverse events, many other health care workers within the programme may not have such capacity. The monitoring component of aDSM is also likely to be novel to many health care workers. WHO/GTB and technical partners will be supporting NTPs to build such capacity and to integrate aDSM into routine PMDT monitoring. A training plan and resources for building capacity will be created by early 2016.

The creation of a global central database to pool anti-TB drug-safety data collected through aDSM projects in different countries is envisaged from mid-early 2016. This could increase the likelihood of detecting rare AEs. Separate guidance will be prepared to help national programmes submit their data to the global database.



**BOX 2. SUMMARY – aDSM IN BRIEF**

- Active TB drug-safety monitoring and management (aDSM) refers to active and systematic clinical and laboratory assessment of patients on treatment with new anti-TB drugs, novel MDR-TB regimens or XDR-TB regimens to detect, manage and report suspected or confirmed drug toxicities.
- While all detected adverse events (AEs) need to be managed clinically, the core package of aDSM requires the reporting of only serious AEs (SAEs). Treatment sites with additional resources may also monitor other AEs that are of clinical significance or of special interest to the programme, as part of comprehensive aDSM. aDSM may also be expanded in a phased approach to eventually cover TB patients on treatment with any second-line drugs should programmes wish to do so.
- aDSM is intended to be an integral component of the programmatic management of drug-resistant TB (PMDT). Its rationale is based on recent developments in MDR-TB treatment, particularly the approval for use of new medicines ahead of the completion of Phase III trials, increased use of repurposed drugs for XDR-TB treatment and the development of novel second-line anti-TB regimens. Such approaches need careful monitoring for drug-related harms, some of which may not have been described as yet.
- aDSM is not aimed at replacing or duplicating efforts of national pharmacovigilance units but to complement current capacities and address barriers to undertake active pharmacovigilance within the context of TB care. In addition to drug-safety monitoring, aDSM also incorporates a component that promotes the clinical management of all ADRs and AEs regardless of their seriousness. This monitoring and management needs to be adapted to the realities of TB programmes that are often under-resourced.
- For national TB programmes (NTPs) to undertake aDSM effectively, a series of activities need to be coordinated to ensure that: the right expertise is developed through interaction with local and external drug-safety experts; sufficient funds are made available so that clinical monitoring activities are performed, data gets collected, reported and analysed; and decisions are made on the basis of new knowledge gained.

## Annex 1. List of contributors

Alberto Piubello  
Action Damien

Alena Skrahina  
National TB Programme, Belarus

Alex Golubkov  
United States Agency for  
International Development

Amy Bloom  
United States Agency for  
International Development

Ana Scardigli  
The Global Fund to Fight AIDS,  
Tuberculosis and Malaria

Antonia Kwiecien  
Management Sciences for Health

Arnaud Trébucq  
UNION

Brian Kaiser  
UNITAID

Francis Varaine  
Médecins Sans Frontières  
(representing the EndTB project)

Janet Ginnard  
UNITAID

Nguyen Thi Thuy  
National TB Programme, Viet Nam

Nguyen Viet Nhung  
National TB Programme, Viet Nam

Philipp du Cros  
Médecins Sans Frontières

Susan van den Hof  
KNCV Tuberculosis Foundation

### WHO/Headquarters

Christian Lienhardt (GTB)

Christine Halleux (TDR)

Dennis Falzon (GTB)

Ernesto Jaramillo (GTB)

Fuad Mirzayev (GTB)

Karin Weyer (GTB)

Lembit Rago (EMP)

Linh Nguyen (GTB)

Mario Raviglione (GTB)

Piero Olliaro (TDR)

Shanthi Pal (EMP)

## Annex 2. Glossary of terms for active tuberculosis drug-safety monitoring and management (aDSM)

*In addition to the new terms (marked with an asterisk), the definition of other terms may have been modified slightly from those in general usage to apply better to the context of NTPs.*

**active TB drug-safety monitoring and management (aDSM)** is the active and systematic, clinical and laboratory assessment of patients on treatment with new anti-TB drugs, novel MDR-TB regimens, or XDR-TB regimens, to detect, manage and report suspected or confirmed drug toxicities. While all detected adverse events (AEs) need to be managed, the core package of aDSM requires the reporting of serious AEs (SAEs) only. M/XDR-TB treatment sites with additional resources may also monitor other AEs that are of clinical significance or of special interest to the programme, as part of comprehensive aDSM.

**adverse drug reaction (ADR)** is a response to a TB medicine that is noxious and unintended, and which occurs at doses normally used in humans.

**adverse event (AE)** is any untoward medical occurrence that may present in a TB patient during treatment with a pharmaceutical product, but which does not necessarily have a causal relationship with this treatment.

**serious adverse event (SAE)** is an AE which either leads to death or a life-threatening experience; to hospitalization or prolongation of hospitalization; to persistent or significant disability; or to a congenital anomaly. SAEs that do not immediately result in one of these outcomes but that require an intervention to prevent it from happening are included (14). SAEs may require a drastic intervention, such as termination of the drug suspected of having caused the event.

**adverse event of clinical significance** is an AE that is either (i) serious, (ii) of special interest, (iii) leads to a discontinuation or change in the treatment, or (iv) is judged as otherwise clinically significant by the clinician (see Annex 3). The centres that offer the advanced package of aDSM will include all AEs of clinical significance in their reporting.

**adverse event of special interest** is an AE documented to have occurred during clinical trials and for which the monitoring programme is specifically sensitized to report regardless of its seriousness, severity or causal relationship to the TB treatment (see Annex 3). The centres that offer intermediate and advanced packages of aDSM will include all AEs of special interest in their reporting.

**adverse event leading to treatment discontinuation or change in drug dosage**, is one that leads a clinician to stop, interrupt temporarily or change the dosage of one or more drugs, regardless of its seriousness, severity, or causal relationship to the TB treatment.

**causal relationship** is a relationship between an exposure (A) and an event (B) in which A precedes and causes B. This may refer to the causal association between an exposure to a TB medicine and the occurrence of an adverse reaction.

**causality assessment** is the evaluation of the likelihood that a TB medicine was the causative agent of an observed adverse reaction.

**drug-safety profile** is a description of the benefits, risks and toxicity of a given TB drug or regimen, specifying any known or likely safety concerns, contraindications, cautions, preventive measures and other features that the user should be aware of to protect the health of a TB patient.

**sentinel sites** are centres that, in addition to the core package of aDSM, undertake intermediate or advanced levels of drug-safety monitoring.

**signal** is reported information on a possible causal relationship between an adverse event and a TB medicine, the relationship being unknown or incompletely documented previously or representing a new aspect of a known association. The information may arise from one or multiple sources that are judged to be of sufficient likelihood to justify verification (15).

## Annex 3. Adverse events of clinical significance or special interest for aDSM

See *Annex 2* for the definition of types of adverse events mentioned on this page.

1. All serious adverse events (SAEs).
2. All AEs of special interest (suggested list):<sup>4</sup>
  - Peripheral neuropathy (paraesthesia)
  - Psychiatric disorders and central nervous system toxicity (e.g. depression, psychosis, suicidal intention, seizures)
  - Optic nerve disorder (optic neuritis) or retinopathy
  - Ototoxicity (hearing impairment, hearing loss)
  - Myelosuppression (manifested as anaemia, thrombocytopenia, neutropenia or leukopenia)
  - Prolonged QT interval (Fridericia correction; see (8))
  - Lactic acidosis
  - Hepatitis (defined as increases in alanine aminotransferase (ALT) or aspartate aminotransferase (AST)  $\geq 5x$  the upper limit of normal (ULN), or increases in ALT or AST  $\geq 3x$  ULN with clinical manifestations, or increases in ALT or AST  $\geq 3x$  ULN with concomitant increase in bilirubin  $\geq 1.5x$  ULN)
  - Hypothyroidism
  - Hypokalaemia
  - Pancreatitis
  - Phospholipidosis
  - Acute kidney injury (acute renal failure).
3. Adverse events leading to treatment discontinuation or change in drug dosage.
4. Adverse events not listed above but judged as otherwise clinically significant by the clinician.

Source: Adapted from (16)

---

<sup>4</sup> The list shown here is provisional and may be modified according to the regimen composition or the patient cohort.

## Annex 4. Clinical and laboratory testing schedule for active tuberculosis drug-safety monitoring and management (aDSM)

To be adapted to the treatment regimen and national policy<sup>1</sup>

|                                    | M0 | M1 | M2 | M3 | M4 | M5 | M6 | M7 | M8 | M9 | M10 | M11 | M12 | M13 | M14 | M15 | M16 | M17 | M18 | M19 | M20 | M21 | M22 | M23 | M24 |  |
|------------------------------------|----|----|----|----|----|----|----|----|----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|--|
| Date                               |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| Clinical screen                    |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| Visual acuity                      |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| Simple hearing test                |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| Audiogram                          |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| Neuro & psychiatric investigations |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| Serum creatinine                   |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| ALT (SGPT)                         |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| AST (SGOT)                         |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| Bilirubin                          |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| Alkaline phosphatase               |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| γGT                                |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| ECG                                |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| Lipase                             |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| Amylase                            |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| Potassium                          |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| Magnesium                          |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| Calcium                            |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| Albumin                            |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| CBC                                |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| Blood glucose                      |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |
| Thyroid tests: TSH                 |    |    |    |    |    |    |    |    |    |    |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |  |

<sup>1</sup> Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis (WHO/HTM/TB/2014.11). Geneva, World Health Organization. 2014

Shade cells for the months when the test will not be done.

Notation for marking the cells: 0= screen/test not done 1=screen/test done; result pending 2=screen/test done; no SAE 3=screen/test done; SAE detected  
 ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase); AST (SGOT)=aspartate aminotransferase (serum glutamic-oxaloacetic transaminase);  
 CBC=complete blood count; ECG=electrocardiogram; γGT=gamma glutamyl transferase; TSH=thyroid stimulating hormone.

# Annex 5. Alert for serious adverse events to the TB programme

**CONFIDENTIAL – To be sent even upon suspicion of a serious adverse event**

**IS THIS REPORT A NEW EVENT?**    YES    NO                      GIVE DATE WHEN PREVIOUS SAE FORM SENT:

DD                      MMM                      YYYY

## 1. PATIENT DETAILS

LAST NAME \_\_\_\_\_ FIRST NAME \_\_\_\_\_

SEX    MALE    FEMALE                      DATE OF BIRTH                          

                         DD                      MMM                      YYYY

*age in yrs if DOB unknown*

PREGNANCY    YES    NO

ID NUMBER \_\_\_\_\_ PHONE NO. \_\_\_\_\_

ADDRESS \_\_\_\_\_

## 2. SUSPECTED and CONCOMITANT MEDICINE(S)

| NAME (Brand name or Generic) | Total daily dose | Date started | Date stopped | Continues                |
|------------------------------|------------------|--------------|--------------|--------------------------|
|                              |                  |              |              | <input type="checkbox"/> |
|                              |                  |              |              | <input type="checkbox"/> |
|                              |                  |              |              | <input type="checkbox"/> |
|                              |                  |              |              | <input type="checkbox"/> |
|                              |                  |              |              | <input type="checkbox"/> |

## 3. DETAILS OF SERIOUS ADVERSE EVENT

DATE EVENT STARTED \_\_\_\_\_ DATE EVENT STOPPED \_\_\_\_\_

DESCRIPTION OF EVENT \_\_\_\_\_

WHY IS THE EVENT CONSIDERED SERIOUS?

Death

Life-threatening event (specify: \_\_\_\_\_)

Hospitalization or prolongation of hospitalization

Persistent or significant disability (specify: \_\_\_\_\_)

Congenital anomaly

Other (specify: \_\_\_\_\_)

| 4. ACTION TAKEN                             | 5. OUTCOME OF SERIOUS ADVERSE EVENT                   |
|---|---|
| <input type="checkbox"/> Medicine withdrawn | <input type="checkbox"/> Recovered / resolved         |
| <input type="checkbox"/> Dose increased     | <input type="checkbox"/> Recovering / resolving       |
| <input type="checkbox"/> Dose reduced       | <input type="checkbox"/> Recovered with sequelae      |
| <input type="checkbox"/> Dose not changed   | <input type="checkbox"/> Not recovered / not resolved |
| <input type="checkbox"/> Unknown            | <input type="checkbox"/> Died                         |
|   | <input type="checkbox"/> Unknown                      |

| 6. REPORTER           |  |
|-----------------------|--|
| NAME _____            | POSITION _____   |
| FACILITY/CLINIC _____ |  |
| ADDRESS _____         |  |
|                       |  |
| E-MAIL _____          | PHONE NO. _____  |
| SIGNATURE _____       | DATE SENT:   |
|                       | <input type="checkbox"/> <input type="checkbox"/> DD <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> MMM <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> YYYY |

### Explanatory Note

#### TO BE ADAPTED ACCORDING TO THE LOCAL SITUATION

- This form is intended for the Core Package of active tuberculosis drug-safety monitoring and management (aDSM). For more details please refer to other documents on aDSM. The spontaneous reporting form in use by the national pharmacovigilance authorities may be adapted to provide for the purposes of alerting the TB programme of SAEs and avoiding parallel reporting structures.
- The completed form can be sent electronically, via email or fax to <address> and the responsible authority alerted by phone.
- The report should be sent within <number> hours after it is detected, even upon suspicion of seriousness.
- The report should be sent even if not all details are available and regardless of certainty of association with any particular medicine. The essential details are the identifiers of the patient and the reporter; the name of the suspected medicine(s); and basic details on the serious adverse event.
- If the report relates to a previously notified event indicate this under section 3; if more than one serious adverse event occur in the same individual, send separate forms for each event.
- All health care professionals are encouraged to report. Patients and relatives may also report.
- Upon receipt of the information the responsible authority will review the information and contact the reporter and/or facility for more details. All information, including identity of the patient and reporter, will be handled in strict confidence. Apart from action to protect public health, anonymised statistics from these reports will be used to improve drug-safety.
- When reporting please use DD MMM YYYY format to report dates. Under DESCRIPTION OF EVENT in section 3, provide a single diagnosis and include anatomical location if applicable. If diagnosis is unknown, describe clinical picture.



# References

1. A practical handbook on the pharmacovigilance of medicines used in the treatment of tuberculosis. Enhancing the safety of the TB patient. Geneva: World Health Organization; 2012 ([www.who.int/medicines/publications/Pharmaco\\_TB\\_web\\_v3.pdf](http://www.who.int/medicines/publications/Pharmaco_TB_web_v3.pdf), accessed 11 January 2016).
2. The use of short regimens for treatment of multidrug-resistant tuberculosis. In: WHO Geneva programmes [website] ([www.who.int/tb/challenges/mdr/short\\_regimen\\_use/](http://www.who.int/tb/challenges/mdr/short_regimen_use/), accessed 11 January 2016).
3. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance (WHO/HTM/TB/2013.6). Geneva: World Health Organization; 2013 ([http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf), accessed 11 January 2016).
4. The use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance (WHO/HTM/TB/2014.23). Geneva: World Health Organization; 2014 ([http://apps.who.int/iris/bitstream/10665/137334/1/WHO\\_HTM\\_TB\\_2014.23\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/137334/1/WHO_HTM_TB_2014.23_eng.pdf), accessed 11 January 2016).
5. Research protocol – effectiveness of a simplified short regimen for multidrug resistant tuberculosis treatment in Karakalpakstan, Uzbekistan. MSF Field Research. (<http://fieldresearch.msf.org/msf/handle/10144/322296>, accessed 11 January 2016).
6. Active pharmacovigilance [website]. Center for Examinations and Tests in Health Service: Belarus; 2015 (<http://www.rceth.by/en/Safety/PharmacovigilanceSafety>, accessed 11 January 2016).
7. MDR-TB study in Francophone Africa [website]. Paris: International Union Against Tuberculosis and Lung Disease; 2013 (<http://old.theunion.org/index.php/en/what-we-do/tuberculosis/mdr-tb-study-in-francophone-africa>, accessed 11 January 2016).
8. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. (WHO/HTM/TB/2014.11). Geneva: World Health Organization; 2014 ([http://apps.who.int/iris/bitstream/10665/130918/1/9789241548809\\_eng.pdf](http://apps.who.int/iris/bitstream/10665/130918/1/9789241548809_eng.pdf), accessed 11 January 2016).
9. Policy implementation package for new TB drug introduction (WHO/HTM/TB/2014.22). Geneva: World Health Organization; 2014 ([www.who.int/tb/PIPnewTBdrugs.pdf](http://www.who.int/tb/PIPnewTBdrugs.pdf), accessed 11 January 2016).
10. Tuberculosis and pharmacovigilance. In: WHO Geneva tuberculosis/challenges [website] (<http://www.who.int/tb/challenges/pharmacovigilance/en/>, accessed 11 January 2016).
11. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: World Health Organization; 2002 ([apps.who.int/medicinedocs/en/d/Js4893e/#Js4893e](http://apps.who.int/medicinedocs/en/d/Js4893e/#Js4893e), accessed 11 January 2016).
12. VigiBase™. In: The Uppsala Monitoring Centre/products and services [website] (<http://www.umc-products.com/DynPage.aspx?id=73590&mn1=1107&mn2=1132>, accessed 11 January 2016).
13. Inter-regional workshop on pharmacovigilance for new drugs and novel regimens for the treatment of drug-resistant tuberculosis. Meeting Report. 12–14 November 2014. Hanoi, Viet Nam (WHO/HTM/TB/2015.07). Geneva: World Health Organization; 2015 ([http://www.who.int/entity/tb/challenges/meeting\\_report\\_pv\\_workshop\\_hanoi\\_2014.pdf](http://www.who.int/entity/tb/challenges/meeting_report_pv_workshop_hanoi_2014.pdf), accessed 11 January 2016).
14. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH Harmonised Tripartite Guideline. Post-approval safety data-management: definitions and standards for expedited reporting E2D. Geneva: International Council for Harmonisation; 2003 ([https://www.ich.org/fileadmin/Public\\_Web\\_Site/ICH\\_Products/Guidelines/Efficacy/E2D/Step4/E2D\\_Guideline.pdf](https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2D/Step4/E2D_Guideline.pdf), accessed 11 January 2016).

15. Guideline on good pharmacovigilance practices (GVP). Annex 1 – Definitions (EMA/876333/2011 Rev 2\* (superseded version). 2013 ([http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Scientific\\_guideline/2014/04/WC500165593.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/04/WC500165593.pdf), accessed 11 January 2016).
16. Pharmacovigilance guideline for endTB projects outside interventional clinical trial. version 0.7. UNITAID, Partners in Health, Médecins sans Frontières, Interactive Research & Development; 2015.



